A systematic literature review of the economic impact of ankylosing spondylitis

Clinical and Experimental Rheumatology

Volumn 30, Issue 4 SUPPL.73, 2012, Pages

  Palla, I ^a   Trieste, L ^a   Tani, C ^c   Talarico, R ^c   Cortesi, P A ^b   Mosca, M ^c   Turchetti, G ^a  

^a SCUOLA SUPERIORE SANT ANNA   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Ankylosing spondylitis; Costs; Loss of productivity; Quality of life; Review

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; TUMOR NECROSIS FACTOR INHIBITOR;

AGE; ANKYLOSING SPONDYLITIS; ARTICLE; COST OF ILLNESS; DISEASE SEVERITY; DRUG EFFICACY; GENDER; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; PATIENT CARE; PRIORITY JOURNAL; PRODUCTIVITY; REIMBURSEMENT; SYSTEMATIC REVIEW;

AGE FACTORS; ANTIRHEUMATIC AGENTS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; FEMALE; HUMANS; MALE; QUALITY OF LIFE; SEX FACTORS; SICK LEAVE; SPONDYLITIS, ANKYLOSING;

EID: 84870287999     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. BOONEN A, MAU W: The economic burden of disease: comparison between rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009;27(Suppl. 55):S112-S117.
2. Centre for Reviews and Dissemination, CRD's guidance for undertaking reviews in health care, 2008, University of York.
3. Cochrane Handbook for Systematic Reviews of interventions, Edited by Higgins J. P. T. and Green S., 2008, Wiley-Blackwell.
4. BOONEN A, VAN DER HEIJDE D, LANDEWÉ R et al.: Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis 2002;6:429-37.
5. BOONEN A, VAN DER HEIJDE D, LANDEWE R et al.: Costs of ankylosing spondylitis in three European countries: the patient's perspective. Ann Rheum Dis 2003;62:741-7.
6. BOONEN A, VAN DER HEIJDE D, LANDEWE R et al.: Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Ann Rheum Dis 2003;62:732-40.
7. BOONEN A, VAN DEN HEUVEL R, VAN TUBERGEN A et al.: Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis. Ann Rheum Dis 2005;64:396-402.
8. VERSTAPPEN S M M, JACOBS J W G, VAN DER HEIJDE DM et al.: Utility and direct costs: ankylosing spondylitis compared with rheumatoid arthritis. Ann Rheum Dis 2007;66:727-31.
9. BOONEN A, BRINKHUIZEN T, LANDEWÉ R, VAN DER HEIJDE D, SEVERENS J: Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. Ann Rheum Dis 2010;69:1123-8.
10. ARA RM, PACKHAM JC AND HAYWOOD KL: The direct healthcare costs associated with ankylosing spondylitis patients attending a UK secondary care rheumatology unit. Rheumatology 2008;47:68-71.
11. RAFIA R, ARA R, PACKH A M, HAYWOOD K, HEALEY E: Healthcare costs and productivity losses directly attributable to ankylosing spondylitis. Clin Exp Rheumatol 2012;30:246-53.
12. WARD M: Functional Disability Predicts Total Costs in Patients With Ankylosing Spondylitis. Arthritis Rheum 2002;46:223-31.
13. STRÖMBECK B, ENGLUND M, BREMANDER A et al.: Cost of illness from the public payers' perspective in patients with ankylosing spondylitis in rheumatological care. J Rheumatol 2010;37:2348-55.
14. KOBELT G, SOBOCKI P, MULERO J, GRATACOS J, POCOVI A, COLLANTES-ESTEVEZ E: The burden of ankylosing spondylitis in Spain. Value in Health 2008;11:408-15.
15. YOUNE SM, JALLE DA, AYDI AZ et al.: Socioeconomic impact of ankylosing spondylitis in Tunisia. Joint Bone Spine 2010;77:41-6.
16. ZHU TY, TAM L, LEE V et al.: Costs and quality of life of patients with ankylosing spondylitis in Hong Kong. Rheumatology 2008;47:1422-5.
17. TORRES T, FERRAZ M, CICONELLI R: Resource utilisation and cost of ankylosing spondylitis in Brazil. Clin Exp Rheumatol 2010;28:490-7.
18. HUSCHER D, MERKESDAL S, THIELE K, ZEIDLER H, SCHNEIDER M, ZINK A: Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 2006;65:1175-83.
19. TRAN-DUY A, BOONEN A, VAN DE LAAR M, FRANKE A, SEVERENS J: A discrete event modelling framework for simulation of longterm outcomes of sequential treatment strategies for ankylosing spondylitis. Ann Rheum Dis 2011;70:2111-8.
20. KOBELT G, ANDLIN-SOBOCKI P, MAKSY-MOWYCH W: Costs and quality of life of patients with ankylosing spondylitis in Canada. J Rheumatol 2006;33:289-95.
21. FRANKE L, AMENT A, VAN DE LAAR M, BOONEN A, SEVERENS J: Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009;27(Suppl. 55):S118-S123.
22. BOONEN A, MAU W: The economic burden of disease: comparison between rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009;27(Suppl. 55):S112-S117.
23. HAMILTON-WEST K, QUINE L: Living with ankylosing spondylitis. The patient's perspective. J Health Psychol 2009;14:820-30.
24. GORDEEV V, MAKSYMOWYCH W, EVERS S, AMENT A, SCHACHNA L, BOONEN A: Role of contextual factors in health-related quality of life in ankylosing spondylitis. Ann Rheum Dis 2010;69:108-12.
25. TAM L-S, CHAN K-Y, LI EK: The influence of illness and variables associated with functional limitations in Chinese patients with ankylosing spondylitis. J Rheumatol 2007;34:5-1032-9.
26. TURCHETTI G, SCALONE L, DELLA CASA ALBERIGHI O et al.: The rationale of pharmacoeconomic analysis in rheumatologic indications. Clin Exp Rheumatol 2012;30(Suppl. 73):S64-S71.
27. FURNERI G, MANTOVANI LG, BELISARI A et al.: Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. Clin Exp Rheumatol 2012;30(Suppl. 73):S72-S84.
28. CORTESI PA, SCALONE L, D'ANGIOLELLA L et al.: Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis. Clin Exp Rheumatol 2012;30(Suppl.73):S126-S131.
29. MOSCA M, BOUMPAS D, BRUCE IN et al.: Treat-to-target in systemic lupus erythematosus: where are we today? Clin Exp Rheumatol 2012;30(Suppl. 73):S112-S115.
30. TURCHETTI G, YAZDANY J, PALLA I, YELIN E, MOSCA M. Systemic lupus erythematosus and the economic perspective: a systematic literature review and points to consider. Clin Exp Rheumatol 2012;30(Suppl. 73):S116-S122.
31. TRIESTE L, PALLA I, BALDINI C et al.: Systemic vasculitis: how little we know about their societal and economic burden. Clin Exp Rheumatol 2012;30(Suppl. 73):S155-S157.
32. TRIESTE L, PALLA I, BALDINI C et al.: Systemic vasculitis: how little we know about their societal and economic burden. Clin Exp Rheumatol 2012;30(Suppl. 73):S154-S156.
33. TURCHETTI G, SPADONI E, GEISLER E: Health technology assessment. Evaluation of biomedical innovative technologies. IEEE Engineering in Medicine and Biology Magazine 2010;29:70-6.